Advanced Preclinical Research Solution for Taterapox Virus Therapeutics & Diagnostics

Overview

Fig.1 ECTV or TATV was used to infect BS-C-1 cells.¹

Taterapox Virus (TATV) belongs to the Poxviridae family and infects mice as its main host species. TATV creates powerful immunosuppression in mice alongside skin ulcer formation and lymph node enlargement, as well as liver and spleen damage. The virus attacks mice through skin lesions, which then spread rapidly across their body systems to suppress their immune functions, making them susceptible to other diseases. Research on TATV uncovers viral strategies to bypass immune detection, which aids in understanding immune system function and virus-host interactions. TATV serves as a crucial resource for vaccine development and antiviral therapy research while facilitating detailed immunological research. Creative Biolabs' preclinical research capabilities for viral studies include the construction of viral vectors and the establishment of animal models to evaluate virus infection and immune responses. Our expert team delivers precise and effective research support that speeds up virological research advances and strengthens vaccine and antiviral treatment development.

Accelerated TATV Preclinical Research Services

• For Therapeutics Development

In Vitro Antiviral Efficacy Assays

• Cytopathic Effect (CPE) Reduction Assays: The assays test compounds for their ability to shield cells from viral damage or cell death, which researchers observe using microscopy or dye uptake techniques.
• Virucidal Assays: The assays test whether a compound can deactivate virus particles outside host cells to prevent infection.
• Cytotoxicity Assays (Cell Viability Assays): These assays establish the threshold concentration where therapeutic agents begin to damage or destroy non-infected cells.
• High-Throughput Screening (HTS): Automated assays enable rapid identification of antiviral leads from extensive compound libraries based on multiple readouts, including CPE or viral protein expression during initial screening.
• Quantitative Polymerase Chain Reaction (qPCR): The method allows researchers to quantify viral nucleic acid (RNA or DNA) levels in both treated and untreated cells to measure how well viral replication is inhibited.

In Vivo Efficacy Studies (Animal Models)

• Efficacy in Reducing Viral Load: Researchers determine viral levels in various tissues and body fluids from treated animals and compare these to control animals.
• Survival Studies: The study evaluates whether the treatment enhances infected animal survival rates when compared to those receiving no treatment.
• Pharmacokinetics (PK): The study focuses on understanding the absorption, distribution, metabolism, and excretion (ADME) processes of the therapeutic agent within the animal body.
• Pharmacodynamics (PD): The study examines how drug concentration levels within the body correlate with their resulting pharmacological effects on viral load reduction.

• For Diagnostics Development

Antigen Detection Assays

• Lateral Flow Immunoassays (LFIA): For rapid, on-site detection of viral antigens.
• Enzyme-Linked Immunosorbent Assay (ELISA): Quantitative and qualitative analysis of TATV proteins in different samples, like serum and swabs.
• Immunofluorescence Assay (IFA): Identifies viral antigens within infected cells or tissues through the application of labeled antibodies.
• Immunohistochemistry (IHC): The IHC technique pinpoints viral antigens within tissue sections used in pathology research.

Nucleic Acid Detection Assays

• Digital PCR (dPCR): Ultra-sensitive quantification of low-level viral DNA.
• Next-Generation Sequencing (NGS): NGS enables scientists to detect complete viral genomes and track mutations while also distinguishing between different viral strains.

Antibody Detection Assays (Serology)

• IgM/IgG ELISA: This test identifies current or previous infections by examining the type of antibody present.
• Western Blot: Confirms antibody specificity against TATV proteins.
• Plaque Reduction Neutralization Test (PRNT): Gold standard for detecting virus-neutralizing antibodies.
• Multiplex Bead-Based Assays (e.g., Luminex): This test identifies antibodies that target multiple antigens or viral strains at once.

Request a Quote

Products for TATV Research

TATV research relies on recombinant proteins because they serve as antigens in serological tests and reveal information about viral structure and function while supporting assays such as ELISA or western blot. Monoclonal antibodies are essential for both viral component isolation and diagnostic processes. These specific viral proteins generate research tools and operate in neutralization assays, which assess immune system reactions.

• Recombinant TATV proteins or antigens

• Antibodies against TATV proteins

Get a Quote Today

Applications

TATV serves multiple research functions, which involve creating vaccines together with advancing gene therapy and developing oncolytic virotherapy treatments. Researchers utilize this model to investigate virus-host interactions as well as poxvirus biology and immune evasion mechanisms. TATV serves as a resource for creating antiviral medications and diagnostic methods, including serological assays and PCR detection. TATV serves as a tool for understanding both zoonotic disease mechanisms and poxvirus evolutionary patterns. TATV proves beneficial for research into immune responses and viral pathogenesis while testing vaccine vector platforms because it shares characteristics with other poxviruses, such as smallpox and monkeypox.

Advantages

• TATV serves as a research model for poxviruses and supporting vaccine development and gene therapy research.
• The expansive genome of Taterapox Virus enables scientists to perform genetic modifications, which positions it as an excellent candidate for developing viral vectors.
• TATV's capacity to target different cell types demonstrates its potential application in oncolytic virotherapy.
• The virus enables researchers to understand how pathogens bypass the immune system detection and spread between species.
• TATV poses fewer biosafety threats than human-infecting poxviruses because it affects non-human hosts, which renders it a more secure option for research in science and medicine.

FAQs